CHIAPPELLA, Annalisa
 Distribuzione geografica
Continente #
NA - Nord America 334
AS - Asia 190
EU - Europa 113
SA - Sud America 8
OC - Oceania 1
Totale 646
Nazione #
US - Stati Uniti d'America 321
CN - Cina 118
IN - India 43
IT - Italia 35
DE - Germania 16
CA - Canada 12
GB - Regno Unito 11
JP - Giappone 11
FR - Francia 7
IE - Irlanda 5
NL - Olanda 5
PH - Filippine 5
TR - Turchia 5
CH - Svizzera 4
CL - Cile 4
HU - Ungheria 4
PL - Polonia 4
DK - Danimarca 3
ES - Italia 3
BE - Belgio 2
BR - Brasile 2
CZ - Repubblica Ceca 2
MK - Macedonia 2
NO - Norvegia 2
RS - Serbia 2
RU - Federazione Russa 2
TW - Taiwan 2
UY - Uruguay 2
VN - Vietnam 2
AU - Australia 1
FI - Finlandia 1
GR - Grecia 1
HK - Hong Kong 1
KR - Corea 1
MX - Messico 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
SG - Singapore 1
Totale 646
Città #
Fairfield 34
Santa Cruz 26
Duncan 25
Shanghai 21
Houston 20
Ann Arbor 18
Ashburn 18
Chennai 17
Seattle 16
Torino 15
Beijing 13
Wilmington 12
Woodbridge 12
Guangzhou 11
Cambridge 9
Buffalo 8
Nanjing 8
Chengdu 5
Chicago 5
Coimbatore 5
Greifswald 5
Munich 5
New York 5
Somerset 5
Tokyo 5
Ankara 4
Changsha 4
Falls Church 4
Nanning 4
Pisa 4
Tianjin 4
Warsaw 4
Bengaluru 3
Copenhagen 3
Des Moines 3
Jinan 3
Las Vegas 3
Raritan 3
Talca 3
Vancouver 3
Changchun 2
Chaoyang 2
Collegeville 2
Dublin 2
El Paso 2
Fleming Island 2
Fuzhou 2
Hangzhou 2
Los Angeles 2
Malolos 2
Manchester 2
Montevideo 2
Naarden 2
Niš 2
Oslo 2
Paris 2
Riva 2
Rochester 2
Saint Louis 2
San Francisco 2
Taipei 2
Tappahannock 2
Winston Salem 2
Wuhan 2
Zurich 2
Ahmedabad 1
Bern 1
Bethesda 1
Birmingham 1
Boardman 1
Boulder 1
Cabanatuan City 1
Caloocan City 1
Carson City 1
Central District 1
Chandler 1
Ciriè 1
Cleveland 1
Columbus 1
Conway 1
Cork 1
Dallas 1
Debrecen 1
Delhi 1
Dong Ket 1
Durham 1
Guangdong 1
Guiyang 1
Gurgaon 1
Göttingen 1
Hamilton 1
Harbin 1
Hefei 1
Helsinki 1
Hyderabad 1
Islamabad 1
Izmir 1
Lausanne 1
Leeds 1
Long Valley 1
Totale 460
Nome #
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma, file e27ce431-ebfa-2581-e053-d805fe0acbaa 397
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials, file e27ce42d-9062-2581-e053-d805fe0acbaa 123
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma, file e27ce42e-f30c-2581-e053-d805fe0acbaa 76
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma, file e27ce42e-2294-2581-e053-d805fe0acbaa 42
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue, file e27ce432-526d-2581-e053-d805fe0acbaa 33
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi, file e27ce432-5f9f-2581-e053-d805fe0acbaa 3
Prognostic role of pre-radiation therapy 18F-fluorodeoxyglucose positron emission tomography for primary mediastinal B-cell lymphomas treated with R-CHOP or R-CHOP-like chemotherapy plus radiation, file e27ce42d-3e17-2581-e053-d805fe0acbaa 2
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death, file e27ce42f-8166-2581-e053-d805fe0acbaa 2
Epigenomic evolution in diffuse large B-cell lymphomas, file e27ce42a-76a9-2581-e053-d805fe0acbaa 1
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial, file e27ce431-f1df-2581-e053-d805fe0acbaa 1
Totale 680
Categoria #
all - tutte 780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 780


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201934 0000 01 02 01894
2019/202062 8333 32 311 15461
2020/202175 66620 35 33 6863
2021/2022375 8361833 3021 4939 61192932
2022/2023134 532719 2023 343 0000
Totale 680